Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000197655 | SCV000250600 | likely benign | not provided | 2021-04-21 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002315604 | SCV000739163 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2021-09-30 | criteria provided, single submitter | clinical testing | The c.1039A>G (p.S347G) alteration is located in exon 7 (coding exon 7) of the MED12 gene. This alteration results from a A to G substitution at nucleotide position 1039, causing the serine (S) at amino acid position 347 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Fulgent Genetics, |
RCV000766102 | SCV000897581 | uncertain significance | X-linked intellectual disability with marfanoid habitus; FG syndrome 1; Blepharophimosis - intellectual disability syndrome, MKB type | 2018-10-31 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV003595889 | SCV001728170 | benign | FG syndrome | 2025-01-01 | criteria provided, single submitter | clinical testing |